 On average the cost per person for orphan drugs is "six times that of non-orphan drugs, a clear indication of their pricing power".Although there are much smaller orphan disease populations, the cost of per-person outlays are the largest and are expected to increase with wider use of public subsidies.In December 2014, the provincial government of Ontario, Canada negotiated the price with the manufacturer, the only drug approved by Health Canada to treat aHUS.